ImmuPharma (LON:IMM) Shares Up 13% – Here’s What Happened

ImmuPharma plc (LON:IMM)’s share price traded up 13% on Friday . The stock traded as high as GBX 2.66 ($0.04) and last traded at GBX 2.32 ($0.03). 12,515,126 shares traded hands during mid-day trading, an increase of 87% from the average session volume of 6,684,644 shares. The stock had previously closed at GBX 2.05 ($0.03).

ImmuPharma Stock Performance

The company’s 50 day moving average price is GBX 2.52 and its 200-day moving average price is GBX 3.04. The company has a market cap of £9.69 million, a price-to-earnings ratio of -3.94 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.